Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.85 HKD | +1.63% |
|
+0.15% | +2.54% |
04-15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
04-15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.54% | 609M | |
+55.32% | 815B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Enrolls 213 Patients for Phase II Trial of Eye Medication in China